Type 1 diabetes mellitus with ketoacidosis with coma
Methodology & AI Transparency ⓘ
Type 1 diabetes mellitus with ketoacidosis with coma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Type 1 diabetes mellitus with ketoacidosis with coma is an ICD-10-CM indexed diagnosis (E10.11) within Type 1 & Type 2 Diabetes.
- 2 Real-world patient consensus: Federal ICD-10-CM code E10.11 categorizes Type 1 diabetes mellitus with ketoacidosis with coma under Type 1 & Type 2 Diabetes.
- 3 Typical cash cost range: Primary evaluation for Type 1 diabetes mellitus with ketoacidosis with coma incorporates hemoglobin A1c tracking [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] and symptom diary review.
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Type 1 diabetes mellitus with ketoacidosis with coma (E10.11): Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] & Fasting Plasma Glucose [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] (75 – 95 mg/dL (E10.11)).
Ask our AI Specialists anything about Type 1 diabetes mellitus with ketoacidosis with coma
What Is Type 1 diabetes mellitus with ketoacidosis with coma?
Type 1 diabetes mellitus with ketoacidosis with coma is an ICD-10-CM indexed diagnosis (E10.11) within Type 1 & Type 2 Diabetes. Clinical evaluation centers on hemoglobin A1c tracking [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] alongside serial Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] tracking (4.8% – 5.6% (< 6.5% clinical target) (E10.11)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Type 1 diabetes mellitus with ketoacidosis with coma (E10.11, Diabetes & Glucose) reflects skeletal muscle GLUT4 in Type 1 diabetes mellitus with ketoacidosis with coma (E10.11: insulin resistance). longitudinal control is benchmarked via Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with ketoacidosis with coma E10.11].
Common Symptoms & Clinical Signs
- • Presentation of Type 1 diabetes mellitus with ketoacidosis with coma (E10.11): elevated fasting blood in Type 1 diabetes mellitus with ketoacidosis with coma (E10.11: glucose or post-meal)
- • Secondary Type 1 diabetes mellitus with ketoacidosis with coma clinical sign: increased thirst [Type 1 diabetes mellitus with ketoacidosis with coma E10.11]
- • Symptom flares in Type 1 diabetes mellitus with ketoacidosis with coma correlating with Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (E10.11)
- • Functional diabetes & glucose impact requiring hemoglobin A1c tracking [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] evaluation (E10.11)
Type 1 diabetes mellitus with ketoacidosis with coma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.11 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] | 4.8% – 5.6% (< 6.5% clinical target) (E10.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] | 75 – 95 mg/dL (E10.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Type 1 diabetes mellitus with ketoacidosis with coma E10.11] | 3.0 – 7.0 uIU/mL (E10.11) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Type 1 diabetes mellitus with ketoacidosis with coma
Treatment selection for Type 1 diabetes mellitus with ketoacidosis with coma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Type 1 diabetes mellitus with ketoacidosis with coma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Randomized trials of telmisartan versus active controls for insulin resistance in: What a 2,033-Participant Study Found When data from all the 33 trials were pooled, telmisartan was associated with statistically significant reductions in percent changes of insulin levels (-10.92%; -15.60% to -6.23%; P < .00001) and HOMA-IR (-15.89%; -22.01% to... Journal of the American Society of Hypertension : JASH • 2014-08-15 • Meta-Analysis | N = 2,033 | 99/100 | PMID 25151319 ↗ |
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Type 1 diabetes mellitus with ketoacidosis with coma Patient Community & “People Like Me” Threads
Filter Type 1 diabetes mellitus with ketoacidosis with coma community threads and patient logs by age, biological sex, dosage, and treatment duration.